Omeros Announces Completion of Acquisition of Assay for GPCR Program
Omeros Corporation , a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has completed the acquisition of a GPCR assay technology, comprised of patents and other intellectual property rights, from Patobios Limited .
Read more on PR Newswire via Yahoo! Finance
Orignal From: Omeros Announces Completion of Acquisition of Assay for GPCR Program
Post a Comment